Abstract
Background: Health research in sub-Saharan Africa takes place against a lengthy history of exploitation and unfair collaboration. This has involved the export of samples and data from the continent for the benefit of institutions and researchers elsewhere. In this paper, we report the perspectives of people involved in conducting genomics research in Zambia and the capacity of the Health Research Act (HRA) of 2013 in regulating genomics research. Methods: We approached 14 purposively selected stakeholders involved in the development or implementation of the HRA in Zambia for in-depth interviews. These were members of research ethics committees, genomics researchers, Ministry of Health policy makers and institutional lawyers. Results: Participants reported that there are benefits in genomics research for Zambia such as diagnosing and treatment of diseases. Participants also expressed concerns, most of which were ethical in nature. Prominent concerns were on consent. Participants’ main concern was the possible misuse of samples in the future. These concerns resonated with the HRA, which prohibits the use of broad consent for the collection of samples and data for future unspecified research. The implications of this is that Zambians may not participate in any kind of health research for which the storage, sharing and re-use of data or samples is envisaged. The restrictive nature of HRA means that genomics research may be excluded from future health research collaborations, thus isolating the country from potentially beneficial health research. Some policy makers also worried the samples and data that comes from such research may be difficult to access by local scientists. Conclusion: In this article, we describe the views of Zambian policymakers on genomics research and the capacity of HRA in regulating genomics research. Our findings are relevant for the Zambian audience, and other African countries that are aiming to regulate health research, especially genomics research.
Highlights
Health research in sub-Saharan Africa takes place against a lengthy history of exploitation and unfair collaboration
In this article, we describe the views of Zambian policymakers on genomics research and the capacity of Health Research Act (HRA) in regulating genomics research
A particular challenge in this regard is that the human capacity and infrastructure required to successfully conduct genomics research remains concentrated in particular African countries (Aron et al, 2017), with others relying on collaboration to make this happen (Yakubu et al, 2018)
Summary
Health research in sub-Saharan Africa takes place against a lengthy history of exploitation and unfair collaboration Characterizing this trend is a history of export of samples and data from the continent for the benefit of institutions and researchers elsewhere (Heymann et al, 2016; Munung et al, 2017). This has involved the export of samples and data from the continent for the benefit of institutions and researchers elsewhere. These concerns resonated with the HRA, which prohibits the use of broad consent for the collection of samples and data for future unspecified research The implications of this is that Zambians may not participate in any kind of health research for which the storage, sharing and re-use of data or samples is envisaged. The restrictive nature of HRA means that genomics research may be excluded from future
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
